Preclinical Development

1 post / 0 new
Tony Rook
Tony Rook's picture
Preclinical Development

Cambridge Healthtech Institute's Second Annual
Preclinical Development

February 22-24, 2006
Moscone North Convention Center
San Francisco, CA

Register by January 20th & Save up to $225!
View Brochure (no form required)


- Microdosing Approach to Compound Selection
- Selecting the Right Model for Preclinical
- Case Study in Drug Redirecting
- Learning from Attrition
- Progress in Predicting Drug Safety
- Profiling Cytotoxic Drugs
- Utilizing Pharmacodynamic Biomarkers
- Extracting Value from Translational Medicine
- Insights from Imaging Biomarkers


ReNAissance: Accelerating Progress
in RNAi Therapeutics
February 21, 2006
1:00-5:00 pm

RNAi Optimization in Vitro and in Vivo
Dr. John Rossi, Professor and Chairman, Department
of Molecular Biology, Beckman Research Institute
of the City of Hope Comprehensive Cancer Center

Peptide-Based Delivery Formulations for siRNA
Dr. Paul H. Johnson, Senior Vice President of
Research and Development and Chief Scientific
Officer, R&D, Nastech Pharmaceutical Company Inc.

Systemic Delivery of Synthetic siRNAs
Dr. Muthiah Manoharan, Vice President, Drug
Discovery, Alnylam Pharmaceuticals

Systemic Delivery of siRNA by Targeted
Dr. Mark Davis, Professor, Chemical Engineering,
California Institute of Technology

Mechanisms of Cholesterol-Conjugated siRNAs
Uptake in Vivo
Dr. Markus Stoffel, Robert & Harriet Heilbrunn
Professor, Lab of Metabolic Diseases, Rockefeller

Stable Nucleic Acid Lipid Particle (SNALP)
Delivery of Nucleic Acid-Based Drugs
Dr. Ian MacLachlan, Chief Scientific Officer,
Protiva Biotherapeutics Inc.

Progress Toward Therapeutic Applications of siRNA
Dr. Barry Polisky, Chief Scientific Officer, Sirna
Therapeutics, Inc.

Preclinical Development of RNAi Therapy for HCV
Dr. Linda Couto, Director, Preclinical Development,

Who Should Attend:

Scientists, Senior Scientists, Heads, Directors,
Senior Directors, Vice Presidents, Senior Vice
Presidents, of Preclinical R&D, Preclinical
Studies, Preclinical & Regulatory Affairs,
Preclinical Discovery, Preclinical Laboratory,
Preclinical Development, Preclinical Sciences,
Preclinical Pharmacology & Toxicology,
Preclinical Biostatistics, Preclinical Models,
Preclinical Biology, and Preclinical Safety

*Separate Registration Required


- Dr. Dominic Spinella, Senior Director Translational
Medicine, Pfizer, Inc

- Dr. James D. Green, Senior Vice President,
Preclinical & Clinical Development Sciences,
Biogen Idec, Inc.

- Dr. Lloyd Stevens, Business Support Manager,
Strategic Business Development, Pharmaceutical
Profiles Ltd.

- Dr. Jeanine L. Bussiere, PhD, DABT, Director of
Toxicology, Amgen Inc.

- Dr. Shama Kajiji, PhD, MBA, Head, Attrition Analysis
Office, Director, Global Project Management,
Pfizer, Inc.

- Dr. Joseph E. Tomaszewski, Acting Associate
Director, and Chief, Toxicology and Pharmacology
Branch, Developmental Therapeutics Program;
and Deputy Director, Division of Cancer
Treatment and Diagnosis, National Cancer Institute

- Dr. Kirk W. Johnson, Vice President, Preclinical
Development, Avigen, Inc.

- Dr. Thomas W. Jones, Director, Toxicology,
Eli Lilly & Co.

- Dr. Heinz-Herbert Fiebig, Oncotest Institute

- Dr. Robert A. Jolly, Biochemical Toxicology,
Lilly Research Laboratories

- Dr. Emily Hickey, Senior Research Fellow,
Infectious Disease, Merck and Co., Inc.

- Dr. Eric A.G. Blomme, Project Leader, Cell and
Molecular Toxicology, Abbott Laboratories

- Dr. William Mattes, Senior Director,
Toxicogenomics, Gene Logic Inc.

- Dr. M. David Green, Supervisory Pharmacologist,
Division of Biological Oncology Products, FDA

- Dr. Roger Luo, Associate Director, Clinical
Discovery, Bristol-Myers Squibb Co.

- Dr. Rakesh Dixit, Senior Director of Toxicology,
Drug Evaluation, Johnson & Johnson, PRD

- Dr. Robert Roth, Professor, Pharmacology and
Toxicology, Michigan State University

- Dr. Zahi A. Fayad, Director, Imaging Science
Laboratory, Radiology and Medicine (Cardiology),
Mount Sinai School of Medicine

- Dr. Robert J. Gillies, Director of Molecular Imaging
and the Cancer Imaging Program, Departments
of Biochemistry & Molecular Biophysics and
Radiology, University of Arizona Cancer Center

- Dr. Robert M. Hoffman, Department of Surgery,
University of California, San Diego, and
AntiCancer Inc.

- Dr. Peter Lassota, Executive Director, Oncology,
Novartis Pharmaceuticals

- Dr. Detlef Stiller, Head, In Vivo Imaging,
Boehringer Ingelheim Pharma GmbH Co